Peptides 101: How BPC-157 & "peptide stacks" are driving wellness culture with NYT's David Dodge and McGill's Jonathan Jarry

Injectable peptide therapy, a controversial wellness trend that caught fire online in 2025, shows no signs of slowing down in 2026 despite an overwhelming lack of safety data. Peptides, especially “research peptides” like BPC-157 and TB-500, have been hailed by famous podcasters, biohackers, and longevity gurus as a miracle cure for just about anything that ails you, from torn ligaments and gut issues to curbing wrinkles and dull skin. There are several well-studied, FDA-approved peptides available today, such as insulin and GLP-1s like Ozempic and Wegovy, but that’s just a sliver of the peptide pie. There are thousands more with glowing online reviews, but scant scientific data, that can be procured online or through longevity clinics. Mixes of various peptides, called “peptide stacks,” often come with clever names like the ‘'wolverine stack’ or ‘glow protocol’, while others have earned names like ‘Barbie peptide’ for their ability to tan the skin without the sun. These popular stacks are not FDA-approved, so they’re distributed online as 'research peptides' that are meant for in-lab research, not human use — a workaround for their gray market status. To find out more, host Lexy Lebsack sat down with two experts on the topic. First up was NYT’s David Dodge (8:42), who walked us through the rise of peptide therapy online. He published an article for NYT in November titled “The internet loves peptide therapy. Is it really a miracle cure?” Lebsack also interviews McGill’s Jonathan Jarry (29:35), who wrote an article in late 2023 — well ahead of a rush of online articles — called “The human lab rats injecting themselves with peptides.” Jarry walks us through the hard science, and lack thereof, of many popular stacks, ahead.